Long‐term safety and efficacy of SGLT2 inhibitor use in older east Asians with type 2 diabetes
Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) have been shown in cardiovascular outcome trials to reduce the risk of heart failure and major adverse cardiovascular as well as renal events in individuals with type 2 diabetes. Moreover, clinical evidence indicates that SGLT2i use reduces heart f...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-01-01
|
| Series: | Journal of Diabetes Investigation |
| Online Access: | https://doi.org/10.1111/jdi.14097 |